Trial · NCT01999218
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach | Ertugliflozin 5 mg | -0.56 | 95% Confidence Interval -0.65 to -0.47 | Percent | |
| Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach | Ertugliflozin 15 mg | -0.64 | 95% Confidence Interval -0.73 to -0.55 | Percent | |
| Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach | Glimepiride | -0.74 | 95% Confidence Interval -0.83 to -0.65 | Percent | |
| Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106 | Ertugliflozin 5 mg | 70.1 | Percentage of Participants | ||
| Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106 | Ertugliflozin 15 mg | 71.3 | Percentage of Participants | ||
| Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106 | Glimepiride | 69.7 | Percentage of Participants | ||
| Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104 | Ertugliflozin 5 mg | 6.5 | Percentage of Participants | ||
| Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104 | Ertugliflozin 15 mg | 8.0 | Percentage of Participants | ||
| Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104 | Glimepiride | 5.1 | Percentage of Participants | ||
| Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach | Ertugliflozin 5 mg | 3.1 | Percentage of Participants | ||
| Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach | Ertugliflozin 15 mg | 5.2 | Percentage of Participants | ||
| Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach | Glimepiride | 19.2 | Percentage of Participants | ||
| Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach | Ertugliflozin 5 mg | -2.96 | 95% Confidence Interval -3.31 to -2.61 | Kilograms | |
| Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach | Ertugliflozin 15 mg | -3.38 | 95% Confidence Interval -3.73 to -3.03 | Kilograms | |
| Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach | Glimepiride | 0.91 | 95% Confidence Interval 0.56 to 1.25 | Kilograms | |
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach | Ertugliflozin 5 mg | -2.25 | 95% Confidence Interval -3.36 to -1.13 | mmHg | |
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach | Ertugliflozin 15 mg | -3.81 | 95% Confidence Interval -4.91 to -2.71 | mmHg | |
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach | Glimepiride | 0.95 | 95% Confidence Interval -0.15 to 2.06 | mmHg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01999218/results